NCT03135249View on ClinicalTrials.gov

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

November 4, 2020

Study Completion Date

November 4, 2020

Conditions
Multiple Sclerosis (MS)
Interventions
DRUG

Alemtuzumab

Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.

Trial Locations (2)

75216

VA North Texas Health Care System, Dallas

75390

UT Southwestern Medical center, Dallas

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT03135249 - Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis | Biotech Hunter | Biotech Hunter